|
What is PCA3?
|
|
What is the PCA3 test?
|
|
What is the difference between the PCA3 test and PSA?
|
|
What is the most important advantage of the PCA3 test?
|
|
When should I use a PCA3 test?
|
|
Does the PCA3 Score only help in deciding whether a biopsy is needed or can it also aid in differentiating significant (aggressive) from insignificant (indolent) cancer?
|
|
Can the PCA3 Assay be used to monitor progression of prostate cancer during active surveillance?
|
|
Can the PCA3 Score be used for active surveillance?
|
|
Can the PCA3 test be used to monitor disease response and/or recurrence of prostate cancer after local or systemic therapy?
|
|
How will the PCA3 test be done?
|
|
What is the PCA3 Score?
|
|
What is the PCA3 Score?
|
|
What does the PCA3 Score mean?
|
|
How should the PCA3 Score be interpreted?
|
|
How would you explain the value of the PCA3 test for a patient?
|
|
Which physician should I consult to perform a PCA3 test?
|
|
Can every urologist perform the PCA3 test?
|
|
How long do I have to wait for the result of the PCA3 test?
|
|
How much does the PCA3 test cost and is the PCA3 test covered by health insurances?
|
|
Does the volume of the urine sample that is collected for the PCA3 test influence the PCA3 Score?
|
|
5α-reductase inhibitors, such as finasteride and dutasteride, decrease the size of the prostate and the serum PSA level. Do these agents also impact on the PCA3 Score?
|
|
Is the PCA3 Score age-dependent?
|
|
Does testosterone replacement therapy influence the PCA3 Score?
|
|
Is the PCA3 test affected by the presence of a urinary tract infection?
|
|
Does recent ejaculation affect the PCA3 score?
|
|
Does treatment with antibiotics influence the PCA3 Score?
|
|
Can the PCA3 test aid in the decision whether a biopsy is needed in men suspected of having prostate cancer but who have been previously treated for prostatitis?
|
|
Can the PCA3 test aid in the decision whether a biopsy is needed in men suspected of having prostate cancer but who have previously undergone transurethral resection of the prostate (TURP) for benign prostatic hyperplasia (BPH)?
|
|
Can the PCA3 Score aid in the decision to perform a prostate biopsy in men who have known genetic variations linked to an increased prostate cancer risk (e.g. a BRCA2 mutation) either themselves or in their immediate family?
|
|
Would the PCA3 test be a good option for men with a high prostate specific antigen (PSA) level and an enlarged prostate who have had a colostomy, i.e. in whom a prostate biopsy by means of a rectal approach can not be performed?
|
|
Can the PCA3 Score aid in the decision to perform a biopsy in a relatively young patient, with no family history of prostate cancer, a normal digital rectal examination (DRE) and a serum prostate specific antigen level (PSA) at or slightly higher than normal for his age?
|
|
Can the PCA3 Score be used to aid in the decision to perform a biopsy of a patient without a family history of prostate cancer, a normal digital rectal examination and a moderately elevated (low-moderately high) serum prostate specific antigen (PSA) level (e.g. 9.1 ng/mL at an age of 69 years)?
|
|
What are the current problems in the diagnosis of early organ-confined prostate cancer?
|
|
What are the most interesting features of the first gene-based marker for prostate cancer?
|
|
What are currently the main problems in diagnosing prostate cancer?
|
|
How was the PCA3 gene discovered?
|
